The online mail-order pharmacies serve only a small part of the market for prescription-only products. The proportion could increase with the e-prescription. At least that’s what the industry is hoping for.
(Photo: dpa)
Frankfurt It’s a paradox: No stock on the German stock market is doing better this year than Shop Apotheke’s. The titles of the online drug mail order company have risen by more than 100 percent since the beginning of the year. At the same time, the opinions of the analysts are so far apart when it comes to hardly any other paper.
Alexander Thiel from the US investment bank Jefferies increased his price target from 140 to 150 euros on Monday. At the current price of 90 euros, he gives the Shop-Apotheke share almost 70 percent upside potential. At the same time, the analysts at Credit Suisse and the analysis company Kepler Chevreux recently downgraded the share, the lowest price target is EUR 32 – that would correspond to a price drop of more than 60 percent.
This constellation is unusual, especially since the reasons for the optimism and skepticism among the analysts are the same: the planned introduction of e-prescriptions in Germany and a joint venture with the Swiss pharmaceutical service provider Galenica.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Further
Read on now
Get access to this and every other article in the
web and in our app.
Further